African swine fever causes up to 100% fatality in pigs, leading to severe economic losses to the pig sector.

There is currently no commercially available vaccine

Tackling ASF through the development of a vaccine will improve the livelihoods of small-holder pig farmers in SSA

Our innovative approach

- We are employing the highly efficient CRISPR/Cas9 and innovative synthetic biology approaches to fast-track rational development of ASFV vaccine candidates.

Context
- ASFV is a lethal viral disease of pigs, endemic in most SSA countries and continues to expand into new territories in Europe and Asia
- ASFV is a major economic threat to global pig industry.
- Currently, there’s no vaccine against ASFV.
- Previous approaches to generate attenuated ASFV vaccine was cumbersome and largely inefficient
- Urgent need to deploy enabling technologies to generate efficacious vaccine to combat this disease.

Outcomes
- Successfully established CRISPR/Cas9 system for editing ASFV genome.
- Synthetic Biology Platform for rapid modification of ASFV genome.
- Generated 6 ASFV live-attenuated vaccine candidates due to be tested in pigs.
- One manuscript under preparation.

Future steps
- Scale up generation of more live-attenuated ASFV vaccine candidates.
- Post-2021 potential: wider applicability and relevance: these versatile technologies can be applied in generating vaccines for other pathogens; bacteria and parasites, etc.

Partners
FLI (Germany), J. Craig Venter Institute (USA), ILRI.

Project funded by IDRC

The CGIAR Research Program on Livestock thanks all donors & organizations which globally support its work through their contributions to the CGIAR Trust Fund. cgiar.org/funders